Login to Your Account

Partnering A Survival Strategy For Cash-Strapped Companies

By Nuala Moran

Wednesday, October 23, 2002
LONDON - With the capital markets closed, partnering is the only route to survival for biotechnology companies running out of cash. But doing deals is getting harder, with more due diligence, less interest in platform technologies and early stage products, and little appetite for drugs with novel mechanisms of action. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription